scispace - formally typeset
M

Mihaela Angelova

Researcher at Francis Crick Institute

Publications -  43
Citations -  6998

Mihaela Angelova is an academic researcher from Francis Crick Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 14, co-authored 28 publications receiving 3902 citations. Previous affiliations of Mihaela Angelova include French Institute of Health and Medical Research & Pierre-and-Marie-Curie University.

Papers
More filters
Journal ArticleDOI

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

TL;DR: The immunophenoscore was a superior predictor of response to anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) and anti-programmed cell death protein 1 (anti-PD-1) antibodies in two independent validation cohorts and may help inform cancer immunotherapy and facilitate the development of precision immuno-oncology.
Journal ArticleDOI

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Franck Pagès, +120 more
- 26 May 2018 - 
TL;DR: The immunoscore provides a reliable estimate of the risk of recurrence in patients with colon cancer and supports the implementation of the consensus Immunoscore as a new component of a TNM-Immune classification of cancer.
Journal ArticleDOI

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

TL;DR: Assessment of the immune status via Immunoscore provides a potent indicator of tumor recurrence beyond microsatellite-instability staging that could be an important guide for immunotherapy strategies.
Posted ContentDOI

Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade

TL;DR: Cellular characterization of the immune infiltrates revealed a role of cancer-germline antigens in spontaneous immunity and showed that tumor genotypes determine immunophenotypes and tumor escape mechanisms and a scoring scheme for the quantification termed immunophenoscore was developed.